1.98

1.98% -0.04

Pre-market: 1.96 -0.02 -1.01%

Dare Bioscience Inc (DARE)

Overview News Price History Financials Discussions Forecast Stock Split

Dare Bioscience Inc stock is traded at $1.98, with a volume of 221.82K. It is down -1.98% in the last 24 hours and down -8.76% over the past month. Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.

Previous Close:

$2.02

Open:

$2.01

24h Volume:

221.82K

Relative Volume:

0.38

Market Cap:

$29.66M

Revenue:

$1.16M

Net Income/Loss:

$-12.02M

P/E Ratio:

-1.9073

EPS:

-1.0381

Net Cash Flow:

$-10.16M

1W Performance:

+7.03%

1M Performance:

-8.76%

6M Performance:

-13.16%

1Y Performance:

-34.65%

1-Day Range:

$1.97

$2.095

1-Week Range:

$1.85

$2.10

52-Week Range:

$1.27

$9.19

Dare Bioscience Inc Stock (DARE) Company Profile

Name

Dare Bioscience Inc

Sector

Healthcare (1104)

Industry

Biotechnology (621)

Phone

858-926-7655

Address

3655 NOBEL DRIVE, SAN DIEGO, CA

Employee

Twitter

@DareBioscience

Next Earnings Date

2026-05-14

Latest SEC Filings

DARE's Discussions on Twitter

Compare DARE vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
DARE Dare Bioscience Inc	1.98	29.66M	1.16M	-12.02M	-10.16M	-1.0381
VRTX Vertex Pharmaceuticals Inc	450.46	114.33B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	614.98	64.47B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	884.20	54.99B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	287.80	38.42B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	160.06	34.03B	742.00K	-1.37B	-1.07B	-7.0731

Dare Bioscience Inc Stock (DARE) Latest News

Jun 14, 2026

Dare Bioscience (DARE) Holds Near Support After Marginal DeclineSector ETF Flow - newsline.com

Jun 14, 2026

Jun 13, 2026

Daré Bioscience Shareholders Back Governance and Capital Plans - The Globe and Mail

Jun 13, 2026

Jun 12, 2026

Daré Bioscience (NASDAQ: DARE) OKs equity line and boosts incentive plan shares - Stock Titan

Jun 12, 2026

Jun 11, 2026

Dare Bioscience (DARE) director receives 10,000 stock option grant - Stock Titan

Jun 11, 2026

Director Susan L. Kelley receives 10,000 Dare Bioscience (DARE) stock options - Stock Titan

Jun 11, 2026

Director at Dare Bioscience (NASDAQ: DARE) receives 10,000 stock options grant - Stock Titan

Jun 11, 2026

Director Gregory Matz receives 10,000 Dare Bioscience (DARE) stock options - Stock Titan

Jun 11, 2026

Dare Bioscience (DARE) director receives 10,000 stock options at $2.03 strike - Stock Titan

Jun 11, 2026

Daré Bioscience to launch vaginal probiotic product By Investing.com - Investing.com South Africa

Jun 04, 2026

Daré Bioscience Announces the Upcoming Launch of Flora Sync LF5™ Vaginal Probiotic Capsules - The Manila Times

Jun 04, 2026

New vaginal probiotic aims to support comfort — with 30% launch discount - Stock Titan

Jun 04, 2026

May 29, 2026

DARE Stock Price, Quote & Chart | DARE BIOSCIENCE INC (NASDAQ:DARE) - ChartMill

May 29, 2026

May 28, 2026

Dare Bioscience (DARE) Dips 2.15%, Hovers Above Key Support at $2.17ETF NAV Deviation - newsline.com

May 28, 2026

May 27, 2026

Dare Bioscience (DARE) Edges Higher Amid Steady Support LevelsThematic ETF Flow - The Legal Advocate

May 27, 2026

Daré Bioscience reports interim phase 3 data for Ovaprene By Investing.com - Investing.com Nigeria

May 27, 2026

May 26, 2026

Dare Bioscience (DARE) Secures Final $1M Grant from NIH for HPV Treatment - GuruFocus

May 26, 2026

Daré Bioscience receives second $1M NIH funding tranche - Investing.com UK

May 26, 2026

Daré Bioscience receives second $1M NIH funding tranche By Investing.com - Investing.com South Africa

May 26, 2026

Daré Bioscience Receives NIH Funding Award Notice to Advance DARE-HPV, its Novel Investigational Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of Cervical Cancer - The Manila Times

May 26, 2026

Press Release: Daré Bioscience Receives NIH Funding Award Notice to Advance DARE-HPV, Its Novel Investigational Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of Cervical Cancer - Moomoo

May 26, 2026

May 22, 2026